

Trastuzumab emtansine (T-DM1) KATHERINE

PRELIMINARY SCORE

CURATIVE



Scoring of iDFS on the same basis as DFS

NON-CURATIVE



ADJUSTMENTS

Quality of life



Serious and disabling adverse effects



Other adjustments



Trastuzumab emtansine (T-DM1) KATHERINE

FINAL SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE




Overall Survival




Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response



Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Therapeutic Indication: Adjuvant treatment of patients with HER2-positive early breast cancer who have residual invasive disease in the breast and/or lymph nodes after neoadjuvant taxane-based and HER2-targeted therapy
 Experimental Arm: Trastuzumab emtansine (T-DM1)
 Control Arm: Trastuzumab

